VolitionRx Limited announced that it is initiating a study with DKFZ, the German Cancer Research Center, to evaluate VolitionRx's NuQ blood tests for the detection of pancreatic cancer.
This collaboration follows VolitionRx's announcements last year of highly encouraging data from two preliminary studies for pancreatic cancer detection. Results from a 59-patient trial with Lund University in Sweden, published in the journal Clinical Epigenetics, demonstrated a detection rate of 92 per cent (23 of 25) of pancreatic cancer cases at 100 per cent specificity using a panel of four NuQ biomarker assays and the classical CA19-9 cancer biomarker. A second study with Hvidovre Hospital, University of Copenhagen in Denmark, demonstrated that a panel of two NuQ biomarker assays and the classical cancer marker CEA (carcino-embryonic antigen) in an age and gender adjusted panel detected 95 per cent (19 out of 20) of pancreatic cancers at 84 per cent specificity.
VolitionRx's chief executive officer, Cameron Reynolds, added, "VolitionRx plans to launch its first commercial product, a blood test for colorectal cancer, later this year. Because our two preliminary trials for pancreatic cancer have produced such outstanding results, we anticipate this will be followed soon after by a NuQ panel test for pancreatic cancer. This trial with DKFZ allows us to expand our analysis very quickly, with results expected by the end of the year, in a large sample set with a world class institution. If successful, this would be a game changing breakthrough in the diagnosis of this very deadly cancer.
"Interim results from a 4,800 patient retrospective symptomatic population study (Hvidovre Hospital, University of Copenhagen, Denmark), released September 9, 2015: Panel of four NuQ biomarker assays detected 81 per cent of colorectal cancers at 78 per cent specificity and 67 per cent of high-risk adenomas.
Results from a completed prospective study of 121 patients referred for colonoscopy (CHU Dinant Godinne - UCL Namur, in Belgium), released December 8, 2015: Panel of four NuQ biomarker assays detected 91 per cent of colorectal cancer cases at 90 per cent specificity and also detected 67 per cent of high-risk adenomas.
Results from a retrospective study of 430 patients referred for colonoscopy (Hvidovre Hospital, University of Copenhagen, Denmark), released February 17, 2016: Panel of five NuQ biomarker assays demonstrated 75 per cent accuracy in detecting highest-risk pre-cancerous colorectal adenomas and also detected 86 per cent of early (stage I) colorectal cancers at 78 per cent specificity.
Results from a 59-patient retrospective study (Lund University, Sweden) published in Clinical Epigenetics online journal. Interim results from a 4,800 patient retrospective symptomatic population study (Hvidovre Hospital, University of Copenhagen, Denmark), released October 22, 2015: Panel of two NuQ biomarker assays and the classical cancer marker CEA (carcino-embryonic antigen) detected 95 per cent of pancreatic cancers at 84 per cent specificity.
Results from a 537-patient retrospective study (Surrey Cancer Research Institute at University of Surrey, United Kingdom), released April 20, 2016 at the AACR Annual Meeting: A single NuQ biomarker assay detected 71 per cent of early stage I prostate cancer cases and 86 per cent of late stage IV prostate cancer at 93 per cent specificity, which is significantly higher than the commonly-used PSA test reported to detect 53 per cent of prostate cancers at 73 per cent specificity.
Interim results (73 of 240 patients collected and assessed) from a prospective study (Liège University Hospital, Belgium), released November 19, 2015: Panel of four NuQ biomarker assays detected 93 per cent of lung cancers at 91 per cent specificity and differentiated lung cancer from the common lung disease, COPD.
Results from a retrospective study of 78 patients referred for colonoscopy (Liège University Hospital, Belgium), released March 9, 2016: Preliminary data demonstrated 86 per cent accuracy in detecting Idiopathic Pulmonary Fibrosis, a fatal lung disease, at 80 per cent specificity.
